Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;31(7):1360-1366.
doi: 10.1016/j.jsps.2023.05.023. Epub 2023 Jun 1.

The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration's Adverse Event Reporting System

Deemah S Alsuhaibani  1 , Heba H Edrees  2   3 , Thamir M Alshammari  4   5
Affiliations

The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration's Adverse Event Reporting System

Deemah S Alsuhaibani et al. Saudi Pharm J. 2023 Jul.

Abstract

Objectives: This study was designed to assess the disproportionality analyses of adverse drug reactions (ADRs) related to hydroxychloroquine and remdesivir and how ADR reporting fluctuated during the COVID-19 pandemic.

Methods: A retrospective observational study was conducted utilizing the Food and Drug Administration's Adverse Event Reporting System (FAERS) data between 2019 and 2021. The study was conducted in two phases. In the first phase, all reports associated with the drugs of interest were evaluated to assess all related adverse drug reactions. In the second phase, specific outcomes of interest (i.e., QT prolongation and renal and hepatic events) were determined to study their association with the drugs of interest. A descriptive analysis was conducted for all adverse reactions related to the drugs being studied. In addition, disproportionality analyses were conducted to compute the reporting odds ratio, the proportional reporting ratio, the information component, and the empirical Bayes geometric mean. All analyses were conducted using RStudio.

Results: A total of 9,443 ADR reports related to hydroxychloroquine; 6,160 (71.49) patients were female, and higher percentage of patients of both sexes were over the age of 65 years. QT prolongation (1.48%), pain (1.38%), and arthralgia (1.25%) were most frequently reported ADRs during the COVID-19 pandemic. The association of QT prolongation with use of hydroxychloroquine was statistically significant (ROR 47.28 [95% CI 35.95-62.18]; PRR 42.41 [95% CI 32.25-55.78]; EBGM 16.08; IC 4.95) compared with fluoroquinolone. The outcome was serious medical events in 48.01% of ADR reports; 27.42% required hospitalization and 8.61% resulted in death. Of 6,673 ADR reports related to remdesivir, 3,928 (61.13%) patients were male. During 2020, the top three ADR reports were elevated liver function tests (17.26%), acute kidney injury (5.95%) and death (2.84%). Additionally, 42.71% of ADR reports indicated serious medical events; 19.69% resulted in death and 11.71% indicated hospitalization. The ROR and PRR of hepatic and renal events associated with remdesivir were statistically significant, (4.81 [95% CI 4.46-5.19] and 2.96 [95% CI 2.66-3.29], respectively.

Conclusion: Our study showed that several serious ADRs were reported with the use of hydroxychloroquine, which resulted in hospitalization and death. Trends with the use of remdesivir were similar, but to a lesser extent. Therefore, this study showed us that off-label use should be based on thorough evidence-based evaluation.

Keywords: COVID-19; FAERS; Hydroxychloroquine; QT prolongation; Remdesivir.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Map showing the percentage of reporting countries for hydroxychloroquine.
Fig. 2
Fig. 2
Most frequently ADRs reported for hydroxychloroquine during the study period.
Fig. 3
Fig. 3
Map showing the percentage of reporting countries for remdesivir.
Fig. 4
Fig. 4
Most frequently ADRs reported for remdesivir during the study period.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Al Rihani S.B., Smith M.K., Bikmetov R., Deodhar M., Dow P., Turgeon J., Michaud V. Risk of adverse drug events following the virtual addition of COVID-19 repurposed drugs to drug regimens of frail older adults with polypharmacy. J. Clin. Med. 2020;9(8):2591. - PMC - PubMed
    1. Alatawi Y.M., Hansen R.A. Empirical estimation of under-reporting in the US Food and Drug Administration adverse event reporting system (FAERS) Expert Opin. Drug Saf. 2017;16(7):761–767. - PubMed
    1. Alshammari T.M., Larrat E.P., Morrill H.J., Caffrey A.R., Quilliam B.J., LaPlante K.L. Risk of hepatotoxicity associated with fluoroquinolones: a national case–control safety study. Am. J. Health Syst. Pharm. 2014;71(1):37–43. - PubMed
    1. Alshammari T.M., Ata S.I., Mahmoud M.A., Alhawassi T.M., Aljadhey H.S. Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010–2015. Ther. Clin. Risk Manag. 2018;14:803. - PMC - PubMed
    1. Angamo M.T., Mohammed M.A., Peterson G.M. Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis. Infection. 2021:1–15. - PMC - PubMed